Samsung Bioepis Co. Ltd. Deal History & Licensing Activity
Samsung Bioepis Co. Ltd. is a life sciences. Over the past three years, Samsung Bioepis Co. Ltd. has been involved in 1 licensing and acquisition transaction, with a primary focus on Antibodies (2 deals). The company currently has 2 active clinical trials, primarily in Immunology.
Deals (12mo)
2
Active Trials
2
Top Modality
Antibodies
Focus Area
Immunology
Samsung Bioepis Co. Ltd. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Samsung Bioepis Co. Ltd. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| SB36 | Sandoz | Antibodies | Unknown | license | Mar 2026 |
Samsung Bioepis Co. Ltd. Pipeline Focus
Therapeutic areas and modalities where Samsung Bioepis Co. Ltd. is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Samsung Bioepis Co. Ltd. Clinical Pipeline
Samsung Bioepis Co. Ltd. has 2 active clinical trials across 2 development phases.
1
Phase 1
1
Phase 3
See How Your Asset Matches Samsung Bioepis Co. Ltd.'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Samsung Bioepis Co. Ltd. Licensing & Deal Activity
Samsung Bioepis Co. Ltd. is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Samsung Bioepis Co. Ltd. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Samsung Bioepis Co. Ltd. include Immunology (2 deals and trials), and Solid Tumors (2 deals and trials). In terms of modality, Samsung Bioepis Co. Ltd. has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Samsung Bioepis Co. Ltd. and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Samsung Bioepis Co. Ltd.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.